Predicting Radiation Esophagitis Using 18F-FDG PET During Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer

被引:19
作者
Mehmood, Qurrat [1 ,2 ]
Sun, Alexander [1 ,2 ]
Becker, Nathan [1 ,2 ]
Higgins, Jane [1 ,2 ]
Marshall, Andrea [1 ,2 ]
Le, Lisa W. [3 ]
Vines, Douglass C. [1 ]
McCloskey, Paula [1 ,2 ]
Ford, Victoria [1 ,2 ]
Clarke, Katy [1 ,2 ]
Yap, Mei [1 ,2 ]
Bezjak, Andrea [1 ,2 ]
Bissonnette, Jean-Pierre [1 ,2 ]
机构
[1] Princess Margaret Canc Ctr, Radiat Med Program, Toronto, ON, Canada
[2] Univ Toronto, Dept Radiat Oncol, Toronto, ON M5S 1A1, Canada
[3] Princess Margaret Canc Ctr, Dept Biostat, Toronto, ON, Canada
关键词
Non-small cell lung cancer; Chemoradiotherapy; Esophagitis; 18-FDG PET; Toxicity; DOSE-ESCALATION; RADIOTHERAPY; FDG; CHEMOTHERAPY; THERAPY; CHEMORADIATION; INTENSITY; IMPACT; VOLUME; TUMOR;
D O I
10.1016/j.jtho.2015.10.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Treatment of locally advanced non-small cell lung cancer with chemoradiotherapy (CRT) is limited by development of toxicity in normal tissue, including radiation esophagitis (RE). Increasingly, F-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) is being used for adaptive planning. Our aim was to assess changes in esophageal FDG uptake during CRT and relate the changes to the onset and severity of RE. Methods: This prospective study in patients with stage II-III non-small cell lung cancer involved serial four-dimensional computed tomography and PET scans during CRT (60-74Gy). RE was recorded weekly using the Common Terminology Criteria for Adverse Events (v4.0), and imaging was performed at weeks 0, 2, 4, and 7. Changes in the esophagus's peak standard uptake value (SUVpeak) were analyzed for each time point and correlated with grade of RE using the Wilcoxon rank-sum test. The volume of esophagus receiving 50 Gy (V50) and volume of esophagus receiving 60 Gy (V60) were correlated with the development of RE, and the C-statistic (area under the curve [AUC]) was calculated to measure predictivity of grade 3 RE. Results: RE developed in 20 of 27 patients (74%), with grade 3 reached in 6 (22%). A significant percentage increase in SUVpeak in the patients with RE was noted at week 4 (p = 0.01) and week 7 (p = 0.03). For grade 3 RE, a significant percentage increase in SUVpeak was noted at week 2 (p = 0.01) and week 7 (p = 0.03) compared with that for less than grade 3 RE. Median V50 (46.3%) and V60 (33.4%) were significantly higher in patients with RE (p = 0.04). The AUC measurements suggested that the percentage change in SUVpeak at week 2 (AUC = 0.69) and V50 (AUC = 0.67) and V60 (AUC = 0.66) were similarly predictive of grade 3 RE. Conclusions: Serial FDG-PET images during CRT show significant increases in SUVpeak for patients in whom RE develops. The changes at week 2 may predict those at risk for the development of grade 3 RE and may be informative for adaptive planning and early intervention. (C) 2015 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:213 / 221
页数:9
相关论文
共 50 条
  • [41] Concurrent chemoradiotherapy for large-volume locally-advanced non-small cell lung cancer
    Wiersma, Terry G.
    Dahele, Max
    Verbakel, Wilko F. A. R.
    van de Ven, Peter M.
    de Haan, Patricia F.
    Smit, Egbert F.
    van Reij, Ellen J. F.
    Slotman, Ben J.
    Senan, Suresh
    LUNG CANCER, 2013, 80 (01) : 62 - 67
  • [42] Oral glutamine supplements reduce concurrent chemoradiotherapy-induced esophagitis in patients with advanced non-small cell lung cancer
    Chang, Shih-Chieh
    Lai, Yi-Chun
    Hung, Jui-Chi
    Chang, Cheng-Yu
    MEDICINE, 2019, 98 (08)
  • [43] Predictors of Acute Radiation Esophagitis in Non-small Cell Lung Cancer Patients Treated With Accelerated Hyperfractionated Chemoradiotherapy
    Wada, Kentaro
    Kishi, Noriko
    Kanayama, Naoyuki
    Hirata, Takero
    Ueda, Yoshihiro
    Kawaguchi, Yoshifumi
    Morimoto, Masahiro
    Konishi, Koji
    Imamura, Fumio
    Ogawa, Kazuhiko
    Teshima, Teruki
    ANTICANCER RESEARCH, 2019, 39 (01) : 491 - 497
  • [44] 18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial
    Cooke, Saskia A.
    de Ruysscher, Dirk
    Reymen, Bart
    Lambrecht, Maarten
    Persson, Gitte Fredberg
    Faivre-Finn, Corinne
    Dieleman, Edith M. T.
    Lewensohn, Rolf
    Diessen, Judi N. A. van
    Sikorska, Karolina
    Lalezari, Ferry
    Vogel, Wouter
    van Elmpt, Wouter
    Damen, Eugene M. F.
    Sonke, Jan -Jakob
    Belderbos, Jose S. A.
    RADIOTHERAPY AND ONCOLOGY, 2023, 181
  • [45] Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer
    Roengvoraphoj, Olarn
    Wijaya, Cherylina
    Eze, Chukwuka
    Li, Minglun
    Dantes, Maurice
    Taugner, Julian
    Tufman, Amanda
    Huber, Rudolf Maria
    Belka, Claus
    Manapov, Farkhad
    STRAHLENTHERAPIE UND ONKOLOGIE, 2018, 194 (02) : 107 - 115
  • [46] 18F-FDG PET/CT radiomics nomogram for predicting occult lymph node metastasis of non-small cell lung cancer
    Qiao, Jianyi
    Zhang, Xin
    Du, Ming
    Wang, Pengyuan
    Xin, Jun
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [47] Predicting treatment outcomes using 18F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy
    Kim, Chang Gon
    Hwang, Sang Hyun
    Kim, Kyung Hwan
    Yoon, Hong In
    Shim, Hyo Sup
    Lee, Ji Hyun
    Han, Yejeong
    Ahn, Beung-Chul
    Hong, Min Hee
    Kim, Hye Ryun
    Cho, Byoung Chul
    Cho, Arthur
    Lim, Sun Min
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [48] Comparison of 18F-FDG PET/CT and MDCT for staging/restaging of non-small cell lung cancer
    Sobic-Saranovic, D.
    Petrusic, I.
    Artiko, V.
    Pavlovic, S.
    Subotic, D.
    Saranovic, D.
    Nagorni-Obradovic, L.
    Petrovic, N.
    Todorovic-Tirnanic, M.
    Odalovic, S.
    Grozdic-Milojevic, I.
    Stoiljkovic, M.
    Obradovic, V.
    NEOPLASMA, 2015, 62 (02) : 295 - 301
  • [49] Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials
    Weber, Wolfgang A.
    Gatsonis, Constantine A.
    Mozley, P. David
    Hanna, Lucy G.
    Shields, Anthony F.
    Aberle, Denise R.
    Govindan, Ramaswamy
    Torigian, Drew A.
    Karp, Joel S.
    Yu, Jian Q.
    Subramaniam, Rathan M.
    Halvorsen, Robert A.
    Siegel, Barry A.
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (08) : 1137 - 1143
  • [50] Chemoradiotherapy in Locally Advanced, Unresectable Non-Small Cell Lung Cancer
    Mitchell, Lauren R.
    Albert, Jeffrey M.
    Lu, Bo
    REVIEWS ON RECENT CLINICAL TRIALS, 2009, 4 (02) : 110 - 121